why choose us

First received: June 26, 2024

Clinical Trial: Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Metabolic Dysfunction-Associated Steatotic Liver Disease

Study Type: INTERVENTIONAL


Official Title: A Phase 2a Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Different Dosing Regimens of Efinopegdutide (MK-6024) in Adults With Metabolic Dysfunction-Associated Steatotic Liver Dis

Brief Summary: This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and tolerability of the different regimens of efinopegdutide.

Read more